TY - JOUR
T1 - The development of interferon-based gene therapy for BCG unresponsive bladder cancer
T2 - from bench to bedside
AU - Duplisea, Jonathan J.
AU - Mokkapati, Sharada
AU - Plote, Devin
AU - Schluns, Kimberly S.
AU - McConkey, David J.
AU - Yla-Herttuala, Seppo
AU - Parker, Nigel R.
AU - Dinney, Colin P.
N1 - Publisher Copyright:
© 2018, Springer-Verlag GmbH Germany, part of Springer Nature.
PY - 2019/10/1
Y1 - 2019/10/1
N2 - Background and Purpose: BCG unresponsive bladder cancer is an inherently resistant disease state for which the preferred treatment is radical cystectomy. To date, no effective intravesical therapies exist for patients who possess these resistant tumors. For this reason, many research groups are actively investigating/testing novel therapeutic agents to aid in bladder preservation for this patient population. This review article describes our 15-year experience developing and testing IFN-based gene therapy. Methods: A comprehensive review was performed of all studies pertaining to IFN-based gene therapy for non-muscle invasive bladder cancer from 2003 to 2018. Results and Conclusions: Over the past two decades, gene therapy has evolved into a powerful tool in our fight against cancer. After overcoming the initial barriers associated with gene delivery to the bladder, we have made significant strides forward in developing this novel therapeutic strategy for the treatment of this inherently resistant disease state. Our results to date are very encouraging; however, much work lies ahead to better understand and optimize this novel approach for treating non-muscle invasive bladder.
AB - Background and Purpose: BCG unresponsive bladder cancer is an inherently resistant disease state for which the preferred treatment is radical cystectomy. To date, no effective intravesical therapies exist for patients who possess these resistant tumors. For this reason, many research groups are actively investigating/testing novel therapeutic agents to aid in bladder preservation for this patient population. This review article describes our 15-year experience developing and testing IFN-based gene therapy. Methods: A comprehensive review was performed of all studies pertaining to IFN-based gene therapy for non-muscle invasive bladder cancer from 2003 to 2018. Results and Conclusions: Over the past two decades, gene therapy has evolved into a powerful tool in our fight against cancer. After overcoming the initial barriers associated with gene delivery to the bladder, we have made significant strides forward in developing this novel therapeutic strategy for the treatment of this inherently resistant disease state. Our results to date are very encouraging; however, much work lies ahead to better understand and optimize this novel approach for treating non-muscle invasive bladder.
KW - BCG unresponsive bladder cancer
KW - Gene therapy
KW - Instiladrin
KW - Interferon-α
UR - http://www.scopus.com/inward/record.url?scp=85056348344&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85056348344&partnerID=8YFLogxK
U2 - 10.1007/s00345-018-2553-7
DO - 10.1007/s00345-018-2553-7
M3 - Review article
C2 - 30415317
AN - SCOPUS:85056348344
SN - 0724-4983
VL - 37
SP - 2041
EP - 2049
JO - World journal of urology
JF - World journal of urology
IS - 10
ER -